ArticleJournal of pharmaceutical policy and practice2022
Management of COVID-19 vaccines cold chain logistics: a scoping review.
Article in Journal of pharmaceutical policy and practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial intelligence in vaccine research and development: an umbrella review.Frontiers in immunology · 2025Pooled it
- Review
- Immunobiological cold chain performance assessment in Brazil: mixed methods research.BMC health services research · 2026Article
- Emerging and Prospective Engineering Technologies Enabling Microneedle Based Vaccine Therapeutics.AAPS PharmSciTech · 2026Review
- Industrial Perspective on the Manufacturing of Lipid Nanoparticles for Nucleic Acid Delivery.Pharmaceutics · 2026Review
- Pharmaceutical design of mRNA vaccines for endemic infectious diseases: integrating antigen discovery with platform engineering.Clinical and experimental vaccine research · 2026Review
- The Current Landscape and Future Prospects of Vaccine Manufacturing in Africa: Challenges, Innovations, and Opportunities: A Narrative Review.Health science reports · 2026Article
- Radiation emergency medical countermeasures: Current formulary, identified gaps, and future approaches.Animal models and experimental medicine · 2025Review
- Article
- Advancements and challenges in next-generation mRNA vaccine manufacturing systems.Clinical and experimental vaccine research · 2025Review
- "Confined Eutectic" Strategy for Visual Refrigeration Responsive Fluorescent Materials with Easy Preparation and Multi-Color Tunability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Randomized-field microwave-assisted pharmaceutical lyophilization with closed-loop control.Scientific reports · 2025Article
- Assessment of eVIN (Electronic Vaccine Intelligence Network) in utility and constraints of various stakeholders in Nainital District: A mixed method study.Journal of family medicine and primary care · 2025Article
- The Impact of Vaccination on COVID-19, Influenza, and Respiratory Syncytial Virus-Related Outcomes: A Narrative Review.Infectious diseases and therapy · 2025Review
- Association Between COVID19 Vaccination Uptake and Socio-Demographic Characteristics Among Pregnant Women in Kenya.The East African health research journal · 2025Article
- Beyond Needles: Immunomodulatory Hydrogel-Guided Vaccine Delivery Systems.Gels (Basel, Switzerland) · 2024Review
- Pandemic-Proofing: Intercepting Zoonotic Spillover Events.Pathogens (Basel, Switzerland) · 2024Review
- A Concise Review of Major Challenges in the Vaccination, Diagnosis and Treatment of Novel Coronavirus Disease 2019.Archives of Razi Institute · 2024Review
- Inhalable Dry Powders for Lung mRNA Delivery.Advanced healthcare materials · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSuccessful mass vaccination programmes are public health achievements of the contemporary world. While pharmaceutical companies are actively developing new vaccines, and demonstrating results of effectiveness and safety profiles, concerns on COVID-19 vaccine management are under-reported. We aimed to synthesise the evidence for efficient cold chain management of COVID vaccines.
methodsThe scoping review's conduct and reporting were based on the PRISMA-ScR 2018 checklist. We searched from April 2020 to January 2022 for publications in PubMed (LitCovid), Scopus and ScienceDirect. All review stages were pilot-tested to calibrate 2 reviewers. Articles on cold chain logistics and management were included, while publications solely describing COVID vaccines, their development and clinical aspects of the vaccine, were excluded. To capture relevant data, charting was conducted by one reviewer and verified by another. Results were analysed thematically and summarised descriptively in a table and in-text. RESULTS AND DISCUSSION: We assessed 6984 potentially relevant citations. We included 14 publications originating from USA (n = 6), India (n = 2), Finland, Spain, Bangladesh, Netherlands, Switzerland and Ethiopia. They were reported as reviews (4), policy or guidance documents (3), experimental studies (2), case reports (2), expert commentary (1), phenomenological study (1), and decision-making trial and evaluation laboratory trial (1). The findings were presented in three themes: (i) regulatory requirements for cold-chain logistics, (ii) packaging and storage, and (iii) transportation and distribution. A conceptual framework emerged linking regulatory requirements, optimal logistics operation and formulation stability as the key to efficient cold chain management. Recommendations were made for improving formulation stability, end-product storage conditions, and incorporating monitoring technologies.
conclusionCOVID-19 vaccines require special end-to-end supply cold chain requirements, from manufacture, and transportation to warehouses and healthcare facilities. To sustain production, minimise wastage, and for vaccines to reach target populations, an efficient and resilient vaccine supply chain which is assisted by temperature monitoring technologies is imperative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.